TMS is FDA-cleared for obsessive-compulsive disorder, but only as an add-on. The first authorization, in August 2018, was BrainsWay's Deep TMS, granted through FDA's De Novo pathway "as an adjunct for the treatment of adult patients suffering from Obsessive-Compulsive Disorder." "Adjunct" means alongside the medication and/or therapy you already have, not instead of them. Each session starts with a few minutes of deliberately stirring up your own obsessions, because the protocol was tested that way.
The pivotal trial showed a real but moderate benefit: after six weeks, 38.1% of people on active treatment met the response bar versus 11.1% on sham. That is a meaningful gain for a hard-to-treat condition. It is not a cure, and most people in the trial did not reach response by the end of treatment. Every OCD clearance is for adults, so TMS for OCD in anyone under 18 is not a cleared use.
What exactly is cleared for OCD
Deep TMS uses a helmet-shaped "H-coil" that reaches broader and somewhat deeper areas than the flat figure-8 coils used in standard depression TMS. The OCD version, usually called the H7 coil, is aimed at the medial prefrontal cortex and the anterior cingulate cortex, regions tied to the brain circuit implicated in OCD. For a full comparison of the coil types, see deep TMS vs standard TMS.
Since 2018, several figure-8 systems have also been cleared for adult OCD, always as an adjunct:
| System | OCD clearance | Wording |
|---|---|---|
| BrainsWay Deep TMS | De Novo DEN170078, Aug 2018 | Adjunct, adults |
| MagVenture | K193006, Aug 2020 | Adjunct, adults |
| NeuroStar Advanced Therapy | K212289, May 2022 | Adjunct, adults |
| Magstim Horizon 3.0 | K243869, Mar 2025 | Adjunct, adults |
| Nexstim NBS 6 | K253098, Mar 2026 | Adjunct, adults |
The clinical trial most people refer to, and the one that defined the symptom-provocation method, used the deep TMS H-coil. If a clinic offers OCD treatment on a different system, it is fair to ask which protocol they use and what evidence sits behind it. TMS devices are "cleared," not "approved"; what FDA clearance means explains the difference.
What a deep TMS session for OCD looks like
The method in the pivotal study is unusual, and it surprises people.
- Provocation. Before each session, your obsessions are deliberately triggered for up to 5 minutes, using prompts tailored to you: an image, an object, a written script about your fear. The trial required distress between 4 and 7 on a visual analog scale before stimulation began. The idea is to have the relevant circuit active while it is stimulated.
- Earplugs and positioning. You wear earplugs rated for at least 30 dB of noise reduction, and the cap is positioned using your motor threshold, measured over the area of the brain that moves your foot.
- Stimulation. In the trial, the coil delivered 20 Hz pulses in 2-second trains with 20-second pauses, 2,000 pulses in all. Each visit lasted about 30 minutes, of which about 20 minutes was stimulation.
- Repeat daily. Sessions ran five days a week for six weeks.
The provocation step is the part most people dread, and the part a good TMS team handles with care. It is brief, it is planned with you, and it resembles the controlled exposure used in OCD therapy. For what the pulses themselves feel like, read what TMS feels like.
What the trials found, with the fine print
The pivotal deep TMS trial (Carmi et al., 2019)
Ninety-nine adults with OCD at 11 centers were randomized to active or sham deep TMS, with symptom provocation before every session, for six weeks. Symptoms were measured on the Yale-Brown Obsessive Compulsive Scale (Y-BOCS), with higher scores meaning more severe OCD. Response was defined as a drop of at least 30%, a lower bar than the 50% usually used for depression.
| Outcome | Active deep TMS | Sham |
|---|---|---|
| Average Y-BOCS drop after 6 weeks | 6.0 points | 3.3 points |
| Response at end of treatment | 38.1% | 11.1% |
| Response 1 month later | 45.2% | 17.8% |
| Completed the study | 89% | 96% |
Source for all rows: Carmi et al., American Journal of Psychiatry, 2019.
Two honest caveats. First, FDA's review notes that the significant difference held in the main modified analysis, but in the full intent-to-treat group the gap was 1.9 points and did not reach statistical significance (p=0.0988), partly because the sham group improved more there. Second, everyone in the trial stayed on stable OCD treatment, medication and/or therapy, which is exactly why the label says "adjunct."
Newer evidence
A 2026 randomized sham-controlled study from India used the H7 coil for just 10 sessions over 2 weeks in 49 people. It reported a Y-BOCS drop of 10.4 vs 2.6 points, with full response in 75% vs 5%. The numbers are striking, but it was small and its short protocol is not the cleared one, so treat it as encouraging rather than settled.
Who TMS for OCD is meant for
Think of TMS as a step for adults whose OCD is still significant despite real effort with first-line care. Good candidates usually:
- have a confirmed OCD diagnosis and are adults, as every OCD clearance requires;
- have tried an adequate course of exposure and response prevention (ERP) and/or an SSRI or similar medication, and are still significantly affected;
- can keep their current treatment steady during the course;
- can attend daily for about six weeks;
- pass the standard safety screen for metal and seizure risk (see TMS with metal implants).
TMS is usually not the right first step if you have never had ERP, if OCD is mild, or if there is active suicidal planning, which needs urgent care first. If you are thinking about suicide or are in crisis, call or text 988 (the 988 Suicide & Crisis Lifeline) or go to the nearest emergency room. FDA's review also lists populations where safety and effectiveness were not established, including people younger than 22 or older than 68, people with a suicide plan or recent attempt, and people with neurological disorders such as a history of seizures. On seizure specifically, a large survey of clinics found the absolute risk low with both coil types, but higher with the H-coil than with the three most-used figure-8 devices combined: 5.56 vs 0.14 per 1,000 patients. These are survey estimates, not trial data. More on that in TMS side effects.
TMS and ERP: partners, not rivals
ERP remains the core psychological treatment for OCD, and nothing in the TMS evidence suggests replacing it. The provocation step even borrows its logic: bring the fear up, then let the brain work while it is active. One useful way to think about TMS is as a possible way to make the next round of ERP more workable for someone who has stalled; that is a clinical rationale, not something the trials tested directly.
A practical plan often looks like this: keep your therapist in the loop before you start, keep medication steady, use your therapist's knowledge of your triggers to design the provocation scripts, and schedule ERP sessions to continue during and after the course. Talking about your obsessions in TMS sessions is structured exposure, not reassurance-seeking; the difference matters, as this piece on why talking about it can make OCD worse explains. For the general case for combining the two, see TMS and talk therapy together, and for what first-line OCD care looks like, starting OCD treatment: the first month.
What the research has not answered yet
It helps to know where the evidence stops, so you can weigh TMS against other next steps with clear eyes.
- How long benefit lasts. The pivotal trial followed people for one month after treatment ended, when the response gap was still present. Longer-term data from controlled trials are thin, and there is no established maintenance schedule for OCD.
- Which coil and protocol is best. The figure-8 OCD clearances did not come with head-to-head comparisons against the H-coil, so no one can say which works better for a given person.
- How many sessions are needed. The cleared course is six weeks of daily sessions; shorter schedules are being tested but are not proven.
- Who is most likely to respond. There is no reliable test that predicts response before you start.
Because of these gaps, a sensible plan sets a review point before treatment begins. Agree with your psychiatrist on how you will judge progress, usually with a Y-BOCS at the start, midway and at the end, and on what you will try next if the change is small. Write down the outcome you would consider worthwhile, too: fewer hours lost to rituals, being able to touch a doorknob, getting to work on time. Those markers keep the decision about continuing grounded in your life, not only in a score.
Insurance and cost: the reality
Coverage for OCD lags behind coverage for depression. Medicare's policy for New York states that deep TMS "is not considered reasonable and necessary" for OCD, which means Original Medicare does not pay for it here. New York Medicaid also states that OCD is not currently an indication it reimburses. Commercial plans vary: Cigna covers deep TMS for adult OCD with criteria, while Aetna and Optum list OCD as experimental or unproven. Before starting, ask the clinic to check your specific plan in writing, and read does insurance cover TMS for how to approach it. If paying out of pocket is on the table, TMS costs without insurance covers the questions to ask.
Questions to ask before you commit
- Which device and which OCD protocol will you use, and is it the cleared one?
- Who designs my provocation, and will you coordinate with my therapist?
- How will you measure progress? (A Y-BOCS at baseline, midway and the end is reasonable.)
- What happens if I have not improved by the end of the course?
- What has my insurer said, in writing?
For broader OCD care, see the practice's OCD treatment page and OCD resources. The TMS guide covers TMS more generally, and the TMS therapy page explains how to start a conversation about it.
Sources
- De Novo Classification Request DEN170078 and De Novo Summary (Brainsway Deep TMS System for OCD). U.S. Food and Drug Administration, 2018. accessdata.fda.gov
- Efficacy and Safety of Deep Transcranial Magnetic Stimulation for Obsessive-Compulsive Disorder: A Prospective Multicenter Randomized Double-Blind Placebo-Controlled Trial. American Journal of Psychiatry (Carmi et al.), 2019. pubmed.ncbi.nlm.nih.gov
- Efficacy of Adjunctive Deep Transcranial Magnetic Stimulation in Obsessive-Compulsive Disorder: A Randomized Sham-Controlled Study. Journal of ECT (Reddy, Goyal, Shreekantiah), 2026. pubmed.ncbi.nlm.nih.gov
- 510(k) K212289, NeuroStar Advanced Therapy for OCD. U.S. Food and Drug Administration, 2022. accessdata.fda.gov
- 510(k) K251119, MagVenture TMS Therapy System. U.S. Food and Drug Administration, 2025. accessdata.fda.gov
- 510(k) K243869, Magstim Horizon 3.0. U.S. Food and Drug Administration, 2025. accessdata.fda.gov
- 510(k) K252358 and K253098, Nexstim NBS 6 System. U.S. Food and Drug Administration, 2026. accessdata.fda.gov
- Seizure risk with repetitive TMS: Survey results from over a half-million treatment sessions. Brain Stimulation (Taylor et al.), 2021. europepmc.org
- Transcranial Magnetic Stimulation, LCD L33398 (version 40). CMS Medicare Coverage Database, 2026. cms.gov
- Efficacy and safety of deep transcranial magnetic stimulation for major depression: a prospective multicenter randomized controlled trial. World Psychiatry (Levkovitz et al.), 2015. pmc.ncbi.nlm.nih.gov
- Transcranial Magnetic Stimulation (Coverage Policy EN0383). Evernorth Health Services (Cigna), 2026. a.static.cigna.com
- Transcranial Magnetic Stimulation and Cranial Electrical Stimulation (Clinical Policy Bulletin 0469). Aetna, 2026. aetna.com
- Behavioral Clinical Policy: Transcranial Magnetic Stimulation (BH803TMS112025). Optum Behavioral Health Solutions, 2026. providerexpress.com
FAQs
Is TMS FDA-approved for OCD?
TMS devices are FDA-cleared, not approved. BrainsWay Deep TMS was first authorized for adult OCD in 2018, as an adjunct to existing treatment, and several other systems have since been cleared for the same use.
Do I have to stop my OCD medication to have TMS?
No. The clearance is as an adjunct, and in the pivotal trial everyone stayed on stable medication and/or therapy. Changes to medication should be planned with your psychiatrist, not made because of TMS.
How many sessions does TMS for OCD take?
The pivotal deep TMS trial used daily sessions, five days a week, for six weeks. Smaller studies have tested shorter schedules, but those are not the cleared protocol.
Will the provocation make my OCD worse?
It is designed to raise distress briefly, to a moderate level, right before stimulation. It is planned with you, and it resembles exposure work in therapy. Tell the team if it feels unmanageable.
Can teenagers get TMS for OCD?
Not as a cleared use. OCD clearances are for adults. The adolescent TMS clearances that exist are for depression, as an add-on, in ages 15 to 21.
